Ovid Therapeutics (OVID) Other Operating Expenses (2016 - 2023)
Ovid Therapeutics (OVID) posted Other Operating Expenses of -$1000.0 for Q1 2023, down 100.12% on a QoQ basis from $836085.0 in Q3 2022, and down 100.48% year-over-year from $209050.0 in Q1 2022.
Ovid Therapeutics (OVID) Other Operating Expenses (2016 - 2023) Analysis & Trends
Ovid Therapeutics' Other Operating Expenses history runs 8 years deep, the most recent figure standing at -$1000.0 for Q1 2023.
- Quarterly Other Operating Expenses fell 100.48% year-over-year to -$1000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was -$1000.0 (down 100.13% YoY) and the FY2021 annual result came in at -$45690.0, down 111.56% from the prior year.
- Other Operating Expenses was -$1000.0 for Q1 2023 at Ovid Therapeutics, down from $836085.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $836085.0 in Q3 2022 and bottomed at -$438260.0 in Q4 2020.
- A 5-year average of $109971.6 and a median of $3280.0 in 2021 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2019 — Other Operating Expenses jumped 58195.11% — and 2022, when it sank 11188.32%.
- Ovid Therapeutics' Other Operating Expenses stood at $298720.0 in 2019, then sank by 246.71% to -$438260.0 in 2020, then surged by 100.89% to $3903.0 in 2021, then surged by 21321.6% to $836085.0 in 2022, then sank by 100.12% to -$1000.0 in 2023.
- Business Quant data shows OVID's Other Operating Expenses at -$1000.0 in Q1 2023, $836085.0 in Q3 2022, and -$284127.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -1,000.00 |
| Sep 30, 2022 | 836,085.00 |
| Jun 30, 2022 | -284,127.00 |
| Mar 31, 2022 | 209,050.00 |
| Dec 31, 2021 | 3,903.00 |
| Sep 30, 2021 | 2,657.00 |
| Jun 30, 2021 | -2,517.00 |
| Mar 31, 2021 | -49,732.00 |
| Dec 31, 2020 | -438,260.00 |
| Sep 30, 2020 | -21,127.00 |
| Jun 30, 2020 | 590,491.00 |
| Mar 31, 2020 | 264,296.00 |
| Dec 31, 2019 | 298,720.00 |
| Sep 30, 2019 | 131,164.00 |
| Dec 31, 2018 | -10,296.00 |
| Sep 30, 2018 | 225.00 |
| Jun 30, 2018 | 304.00 |
| Mar 31, 2018 | 136.00 |
| Dec 31, 2017 | -63.00 |
| Sep 30, 2017 | -112.00 |